1000 related articles for article (PubMed ID: 25409604)
1. Lipid nanoparticles for short interfering RNA delivery.
Leung AK; Tam YY; Cullis PR
Adv Genet; 2014; 88():71-110. PubMed ID: 25409604
[TBL] [Abstract][Full Text] [Related]
2. Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility.
Kulkarni JA; Cullis PR; van der Meel R
Nucleic Acid Ther; 2018 Jun; 28(3):146-157. PubMed ID: 29683383
[TBL] [Abstract][Full Text] [Related]
3. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
[TBL] [Abstract][Full Text] [Related]
4. Lipid Nanoparticle Systems for Enabling Gene Therapies.
Cullis PR; Hope MJ
Mol Ther; 2017 Jul; 25(7):1467-1475. PubMed ID: 28412170
[TBL] [Abstract][Full Text] [Related]
5. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells.
Basha G; Novobrantseva TI; Rosin N; Tam YY; Hafez IM; Wong MK; Sugo T; Ruda VM; Qin J; Klebanov B; Ciufolini M; Akinc A; Tam YK; Hope MJ; Cullis PR
Mol Ther; 2011 Dec; 19(12):2186-200. PubMed ID: 21971424
[TBL] [Abstract][Full Text] [Related]
6. Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA.
Chen S; Tam YYC; Lin PJC; Sung MMH; Tam YK; Cullis PR
J Control Release; 2016 Aug; 235():236-244. PubMed ID: 27238441
[TBL] [Abstract][Full Text] [Related]
7. A novel therapeutic strategy for cartilage diseases based on lipid nanoparticle-RNAi delivery system.
Wang S; Wei X; Sun X; Chen C; Zhou J; Zhang G; Wu H; Guo B; Wei L
Int J Nanomedicine; 2018; 13():617-631. PubMed ID: 29440889
[TBL] [Abstract][Full Text] [Related]
8. Arrayed CRISPR Screening Identifies Novel Targets That Enhance the Productive Delivery of mRNA by MC3-Based Lipid Nanoparticles.
Ross-Thriepland D; Bornot A; Butler L; Desai A; Jaiswal H; Peel S; Hunter MR; Odunze U; Isherwood B; Gianni D
SLAS Discov; 2020 Jul; 25(6):605-617. PubMed ID: 32441189
[TBL] [Abstract][Full Text] [Related]
9. Small molecule ligands for enhanced intracellular delivery of lipid nanoparticle formulations of siRNA.
Tam YY; Chen S; Zaifman J; Tam YK; Lin PJ; Ansell S; Roberge M; Ciufolini MA; Cullis PR
Nanomedicine; 2013 Jul; 9(5):665-74. PubMed ID: 23219877
[TBL] [Abstract][Full Text] [Related]
10. Charge-reversible lipid derivative: A novel type of pH-responsive lipid for nanoparticle-mediated siRNA delivery.
Hirai Y; Saeki R; Song F; Koide H; Fukata N; Tomita K; Maeda N; Oku N; Asai T
Int J Pharm; 2020 Jul; 585():119479. PubMed ID: 32473372
[TBL] [Abstract][Full Text] [Related]
11. Lipid nanoparticles for targeted siRNA delivery - going from bench to bedside.
Zatsepin TS; Kotelevtsev YV; Koteliansky V
Int J Nanomedicine; 2016; 11():3077-86. PubMed ID: 27462152
[TBL] [Abstract][Full Text] [Related]
12. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics.
Maier MA; Jayaraman M; Matsuda S; Liu J; Barros S; Querbes W; Tam YK; Ansell SM; Kumar V; Qin J; Zhang X; Wang Q; Panesar S; Hutabarat R; Carioto M; Hettinger J; Kandasamy P; Butler D; Rajeev KG; Pang B; Charisse K; Fitzgerald K; Mui BL; Du X; Cullis P; Madden TD; Hope MJ; Manoharan M; Akinc A
Mol Ther; 2013 Aug; 21(8):1570-8. PubMed ID: 23799535
[TBL] [Abstract][Full Text] [Related]
13. Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration.
Chen S; Tam YY; Lin PJ; Leung AK; Tam YK; Cullis PR
J Control Release; 2014 Dec; 196():106-12. PubMed ID: 25285610
[TBL] [Abstract][Full Text] [Related]
14. Lipid-based nanoparticles in the systemic delivery of siRNA.
Lin Q; Chen J; Zhang Z; Zheng G
Nanomedicine (Lond); 2014 Jan; 9(1):105-20. PubMed ID: 24354813
[TBL] [Abstract][Full Text] [Related]
15. Targeted siRNA Delivery Using Lipid Nanoparticles.
Jorge A; Pais A; Vitorino C
Methods Mol Biol; 2020; 2059():259-283. PubMed ID: 31435927
[TBL] [Abstract][Full Text] [Related]
16. Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA.
Ball RL; Hajj KA; Vizelman J; Bajaj P; Whitehead KA
Nano Lett; 2018 Jun; 18(6):3814-3822. PubMed ID: 29694050
[TBL] [Abstract][Full Text] [Related]
17. On the role of helper lipids in lipid nanoparticle formulations of siRNA.
Kulkarni JA; Witzigmann D; Leung J; Tam YYC; Cullis PR
Nanoscale; 2019 Nov; 11(45):21733-21739. PubMed ID: 31713568
[TBL] [Abstract][Full Text] [Related]
18. Peptide/Lipid-Associated Nucleic Acids (PLANAs) as a Multicomponent siRNA Delivery System.
Hall R; Alasmari A; Mozaffari S; Mahdipoor P; Parang K; Montazeri Aliabadi H
Mol Pharm; 2021 Mar; 18(3):986-1002. PubMed ID: 33496597
[TBL] [Abstract][Full Text] [Related]
19. Nucleic Acid Delivery System by the Combination of Lipid bubbles and Ultrasound.
Endo-Takahashi Y; Maruyama K; Negishi Y
Curr Pharm Des; 2018; 24(23):2673-2677. PubMed ID: 30084324
[TBL] [Abstract][Full Text] [Related]
20. Next-Generation Lipids in RNA Interference Therapeutics.
Rietwyk S; Peer D
ACS Nano; 2017 Aug; 11(8):7572-7586. PubMed ID: 28727419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
